MB
GPCR icon

MPM BioImpact’s Structure Therapeutics GPCR Stock Holding History

MPM BioImpact’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-230,696
Closed -$9.4M – 39
2023
Q4 		$9.4M Sell
230,696
-65
-0% -$3.73K 2.2% 17
2023
Q3 		$11.6M Buy
+230,761
New +$7.44M 3.11% 11

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

MPM BioImpact's GPCR Position: Q1 2024 in Review

MPM BioImpact sold out of Structure Therapeutics (GPCR) in Q1 2024, closing a stake of 230,696 shares — an estimated $9.4M sold.

MPM BioImpact first reported a position in GPCR in Q3 2023 and held it in 2 quarters. The position peaked at $11.6M in Q3 2023. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

  • MPM BioImpact reported no remaining Structure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • MPM BioImpact sold 230,696 Structure Therapeutics shares in Q1 2024, an estimated $9.4M.
  • MPM BioImpact first reported a position in Structure Therapeutics in Q3 2023 and held it in 2 quarters.
  • MPM BioImpact's Structure Therapeutics position peaked at $11.6M in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.